Efficacy and Safety Profile of Berberine Treatment in Improving Risk Factors for Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized, Double-blind Trials
暂无分享,去创建一个
[1] Interpretation of the Annual Report on Cardiovascular Health and Diseases in China 2020 , 2022, Cardiology Discovery.
[2] Linhong Wang,et al. Prevalence and Treatment of Diabetes in China, 2013-2018. , 2021, JAMA.
[3] Yibin Feng,et al. Adjunctive berberine reduces antipsychotic‐associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial , 2021, Psychiatry and clinical neurosciences.
[4] Pingna Zhang,et al. The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2021, Oxidative Medicine and Cellular Longevity.
[5] Xiaokai Wang,et al. Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study , 2021, Genome Medicine.
[6] H. Tse,et al. Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial , 2021, Nutrients.
[7] Yulan Ye,et al. Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials , 2021, Frontiers in Pharmacology.
[8] Francesca N. Delling,et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. , 2021, Circulation.
[9] I. Atherton,et al. Berberine for the treatment of hypertension: A systematic review. , 2020, Complementary therapies in clinical practice.
[10] Sathish Kumar Jayapal,et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 , 2020, Journal of the American College of Cardiology.
[11] Junhua Li,et al. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study) , 2020, Nature Communications.
[12] E. Martínez-Abundis,et al. Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial. , 2020, Journal of medicinal food.
[13] Hui-Min Yang,et al. [Systematic review and Meta-analysis on efficacy and safety of berberine for dyslipidemia]. , 2020, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.
[14] H. Guan,et al. Berberine treatment-emergent mild diarrhea associated with gut microbiota dysbiosis. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[15] A. Sureda,et al. Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics , 2019, Theranostics.
[16] Hao Xu,et al. Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials. , 2018, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[17] W. Jia,et al. Restoration of GLP-1 secretion by Berberine is associated with protection of colon enterocytes from mitochondrial overheating in diet-induced obese mice , 2018, Nutrition & Diabetes.
[18] Longyun Peng,et al. [Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia]. , 2016, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.
[19] W. Cho,et al. Pharmacological effects of berberine and its derivatives: a patent update , 2016, Expert opinion on therapeutic patents.
[20] Junhua Wang,et al. Renoprotective effects of berberine as adjuvant therapy for hypertensive patients with type 2 diabetes mellitus: Evaluation via biochemical markers and color Doppler ultrasonography. , 2015, Experimental and therapeutic medicine.
[21] Yanyun Zhao,et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. , 2015, Journal of ethnopharmacology.
[22] B. Liu,et al. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment , 2014, Clinical endocrinology.
[23] Jian-Dong Jiang,et al. Excretion of berberine and its metabolites in oral administration in rats. , 2013, Journal of pharmaceutical sciences.
[24] D. Ghareeb,et al. In vitro biological assessment of berberis vulgaris and its active constituent, berberine: antioxidants, anti-acetylcholinesterase, anti-diabetic and anticancer effects , 2013, BMC Complementary and Alternative Medicine.
[25] A. D'Angelo,et al. Effects of berberine on lipid profile in subjects with low cardiovascular risk , 2013, Expert opinion on biological therapy.
[26] Wei-Jia Kong,et al. Protein kinase D activation stimulates the transcription of the insulin receptor gene , 2010, Molecular and Cellular Endocrinology.
[27] Michele Tarsilla. Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.
[28] V. Mercurio,et al. Cardiovascular and metabolic effects of Berberine. , 2010, World journal of cardiology.
[29] Wei-Jia Kong,et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. , 2010, Metabolism: clinical and experimental.
[30] Jingwen Liu,et al. Hepatocyte Nuclear Factor 1α Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine* , 2009, The Journal of Biological Chemistry.
[31] M. Lane,et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. , 2009, American journal of physiology. Endocrinology and metabolism.
[32] Guangji Wang,et al. Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats. , 2008, The Journal of endocrinology.
[33] Satoru Inaba,et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins , 2004, Nature Medicine.
[34] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[35] R. Tweedie,et al. A Nonparametric “Trim and Fill” Method of Accounting for Publication Bias in Meta-Analysis , 2000 .
[36] A R Jadad,et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.
[37] E. Martínez-Abundis,et al. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. , 2013, Metabolic syndrome and related disorders.
[38] Gu Yuan-yuan. Therapeutic effect of berberine combined with Diane-35 on patients with Polycystic ovary syndrome and insulin resistance , 2011 .
[39] Wei-Jia Kong,et al. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. , 2009, Metabolism: clinical and experimental.
[40] Jianping Ye,et al. Berberine improves glucose metabolism through induction of glycolysis. , 2008, American journal of physiology. Endocrinology and metabolism.